Patient Experience and Acceptance of Horizontal Rotation

NCT02995603 | Terminated

• 1 other identifier: Nano-X V1
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

Patients will complete validated psychometric questionnaires to quantify their experience of being rotated at different speeds using the Nano-X patient rotation system.

Conditions

Cancer

Keywords

Radiotherapy; Rotation

Outcome Measures

Primary Outcomes (3)

• Change in level of patient anxiety following rotation in the Nano-X Patient Rotation System

  Comparison of mean scores of Short Form State/Trait Anxiety Inventory (STAI) Questionnaire outcomes before and after being rotated in the Nano-X Patient Rotation System

  1 hour

• Change in level of patient motion sickness following rotation in the Nano-X Patient Rotation System

  Comparison of mean scores of Fast Motion Sickness Test (FMS) Questionnaire outcomes before and after being rotated in the Nano-X Patient Rotation

  1 hour

• Correlation between claustrophobia and the change in anxiety and motion sickness of patients following rotation in the Nano-X Patient Rotation System

  Correlation between Claustrophobia Questionnaire (CLQ) scores prior to study participation on the anxiety and motion sickness results measured in Outcome 1 and Outcome 2

  1 year

Study Arms (1)

Patient rotation

EXPERIMENTAL

Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.

Device: Nano-X patient rotation

Interventions

Nano-X patient rotation DEVICE

Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.

Patient rotation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A diagnosis of cancer, any stage
• ≥18 years of age
• Eastern Cooperative Oncology Group (ECOG) status 0-2
• Currently or previously being treated with radiotherapy
• Any prior therapy allowed
• Willing and able to comply with all study requirements
• Must be able to read and complete questionnaires in English
• Signed, written informed consent

You may not qualify if:

• Pregnant women
• Mentally impaired patients or patients for whom attaining informed consent would be difficult (including language barriers)
• Severe vertigo or recent diagnosis of Benign Paroxysmal Positioning Vertigo

Sponsors & Collaborators

• University of Sydney: lead
• Prince of Wales Hospital, Sydney: collaborator

Study Sites (1)

Prince of Wales Hospital

Randwick, New South Wales, 2031, Australia

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Paul Keall, Prof

  University of Sydney

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2016
• First Posted: December 16, 2016
• Study Start: December 14, 2019
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: May 19, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)